Participants received multiple IV dose of placebo every 4 weeks (Q4W) for 72 weeks.

Participants received multiple IV dose of 10 mg/kg LY3002813 Q4W for 72 weeks.

Participants received multiple IV dose of 20 mg/kg LY3002813 Q4W for 72 weeks.

Administered IV

AUCtau of LY3002813 at steady state (Day 127 [10 mg/kg Q2W] for part B and Day 141 [10 mg/kg and 20 mg/kg Q4W]) for Part C following multiple dose administration of LY3002813 was evaluated.

Maximum serum concentration of LY3002813 during one dosing interval at day 1 was reported.

Cmax of LY3002813 at steady state (Day 127 [10 mg/kg Q2W] for part B and Day 141 [10 mg/kg and 20 mg/kg Q4W]) for Part C following multiple dose administration of LY3002813 was evaluated.

Blood samples were tested to determine if a participant reacted to LY3002813 by producing anti-LY3002813 antibodies. Samples were identified as TE-ADAs if the post-treatment sample had an increase of at least 4 fold in titer from pre-treatment values. If the pre-treatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence. The percentage of participants with TE ADA was calculated as: (the number of participants with TE ADA / total number of participants with at least 1 post-treatment immunogenicity sample analyzed)*100.

Participants received single IV dose of 20 mg/kg LY3002813.

Participants received single IV dose of 40 mg/kg LY3002813.

Participants received multiple IV doses of placebo every 2 weeks (Q2W) for 24 weeks.

Participants received multiple IV doses of 10 mg/kg LY3002813 Q2W for 24 weeks.

Participants received multiple IV doses of placebo every 4 weeks (Q4W) for 72 weeks.

Participants received multiple IV doses of 10 mg/kg LY3002813 Q4W for 72 weeks.

Participants received multiple IV doses of 20 mg/kg LY3002813 Q4W for 72 weeks.

Total of all reporting groups

Participants received single IV dose of 10 mg/kg LY3002813.

Participants received single IV dose of 20 mg/kg LY3002813.

Participants received single IV dose of 40 mg/kg LY3002813.

Participants received multiple IV doses of 10 mg/kg LY3002813 Q2W for 24 weeks.

Participants received multiple IV doses of 10 mg/kg LY3002813 Q4W for 72 weeks.

Participants received multiple IV doses of 20 mg/kg LY3002813 Q4W for 72 weeks.

Area under the curve from time zero to last quantifiable concentration [AUC (0-tlast)] at day 1 was reported.

All randomized participants from part A who received at least one dose of study drug and had evaluable PK data.

Area under the concentration versus time curve during one dosing interval at day 1 was reported.

All randomized participants from part B and part C who received at least one dose of study drug and had evaluable PK data.

AUCtau of LY3002813 at steady state (Day 127 [10 mg/kg Q2W] for part B and Day 141 [10 mg/kg and 20 mg/kg Q4W]) for Part C following multiple dose administration of LY3002813 was evaluated.

All randomized participants from part B and part C who received at least one dose of study drug and had evaluable PK data.

Maximum serum concentration of LY3002813 during one dosing interval at day 1 was reported.

All randomized participants who received at least one dose of study drug and had evaluable PK data.

Cmax of LY3002813 at steady state (Day 127 [10 mg/kg Q2W] for part B and Day 141 [10 mg/kg and 20 mg/kg Q4W]) for Part C following multiple dose administration of LY3002813 was evaluated.

All randomized participants from part B and C who received at least one dose of study drug and had evaluable PK data.

Blood samples were tested to determine if a participant reacted to LY3002813 by producing anti-LY3002813 antibodies. Samples were identified as TE-ADAs if the post-treatment sample had an increase of at least 4 fold in titer from pre-treatment values. If the pre-treatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence. The percentage of participants with TE ADA was calculated as: (the number of participants with TE ADA / total number of participants with at least 1 post-treatment immunogenicity sample analyzed)*100.

All randomized participants who received at least one dose of study drug & had least one non-missing test result for ADA for each of the baseline period and the post-baseline period.

Participants received single IV dose of 10 mg/kg LY3002813.

Participants received single IV dose of 20 mg/kg LY3002813.

Participants received single IV dose of 40 mg/kg LY3002813.

Participants received multiple IV doses of placebo Q2W for 24 weeks.

Participants received multiple IV doses of 10 mg/kg LY3002813 Q2W for 24 weeks.

Participants received multiple IV doses of placebo Q4W for 72 weeks.

Participants received multiple IV doses of 10 mg/kg LY3002813 Q4W for 72 weeks

Participants received multiple IV doses of 20 mg/kg LY3002813 Q4W for 72 weeks.